{"transactions":[{"id":4628974,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-10-02T21:50:48.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":26700,"derivative":{"exercise_price":1.6,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001584759-26-000017","document":"form4-10022026_091044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1796280/000158475926000017/form4-10022026_091044.xml","form_type":"4"}},{"id":4628973,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-02T21:50:48.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":12.9141,"value":41325.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":203472,"source":{"system":"sec-edgar","filing":"0001584759-26-000017","document":"form4-10022026_091044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1796280/000158475926000017/form4-10022026_091044.xml","form_type":"4"}},{"id":4628972,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-02T21:50:48.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3500,"price":12.9141,"value":45199.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":38300,"source":{"system":"sec-edgar","filing":"0001584759-26-000017","document":"form4-10022026_091044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796280/000158475926000017/form4-10022026_091044.xml","form_type":"4"}},{"id":4628971,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-02T21:50:48.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":3500,"price":1.6,"value":5600.0,"ownership":{"direct":true},"balance_after":41800,"source":{"system":"sec-edgar","filing":"0001584759-26-000017","document":"form4-10022026_091044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796280/000158475926000017/form4-10022026_091044.xml","form_type":"4"}},{"id":702057,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-28T20:15:14.000Z","date":"2026-07-24","kind":"exercise","planned":true,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":30200,"derivative":{"exercise_price":1.6,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001584759-26-000015","document":"form4-07282026_080709.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000015/form4-07282026_080709.xml","form_type":"4"}},{"id":702056,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-28T20:15:14.000Z","date":"2026-07-24","kind":"sale","planned":true,"acquired":false,"shares":6100,"price":12.02,"value":73322.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":206672,"source":{"system":"sec-edgar","filing":"0001584759-26-000015","document":"form4-07282026_080709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000015/form4-07282026_080709.xml","form_type":"4"}},{"id":702055,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-28T20:15:14.000Z","date":"2026-07-24","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":12.02,"value":84140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."}],"balance_after":38300,"source":{"system":"sec-edgar","filing":"0001584759-26-000015","document":"form4-07282026_080709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000015/form4-07282026_080709.xml","form_type":"4"}},{"id":702054,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-28T20:15:14.000Z","date":"2026-07-24","kind":"exercise","planned":true,"acquired":true,"shares":3500,"price":1.6,"value":5600.0,"ownership":{"direct":true},"balance_after":45300,"source":{"system":"sec-edgar","filing":"0001584759-26-000015","document":"form4-07282026_080709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000015/form4-07282026_080709.xml","form_type":"4"}},{"id":712462,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T20:35:31.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":300,"price":12,"value":3600.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":212772,"source":{"system":"sec-edgar","filing":"0001584759-26-000012","document":"form4-07082026_080727.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000012/form4-07082026_080727.xml","form_type":"4"}},{"id":893385,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-19T23:38:29.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":1230,"price":26.1759,"value":32196.357,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the \"Heyman Daigle Trust\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Heyman Daigle Trust."}],"balance_after":22647,"source":{"system":"sec-edgar","filing":"0001584759-26-000009","document":"form4-02192026_110223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000009/form4-02192026_110223.xml","form_type":"4"}},{"id":901020,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T01:00:10.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":19234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date."}],"balance_after":19234,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":19234},"source":{"system":"sec-edgar","filing":"0001584759-26-000008","document":"form4-02182026_010204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000008/form4-02182026_010204.xml","form_type":"4"}},{"id":933404,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T22:33:16.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":718,"price":26.956,"value":19354.408,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the \"Heyman Daigle Trust\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $26.725 to $27.3454. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Heyman Daigle Trust."}],"balance_after":23877,"source":{"system":"sec-edgar","filing":"0001584759-26-000007","document":"form4-01222026_100111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000007/form4-01222026_100111.xml","form_type":"4"}},{"id":933403,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T22:33:16.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":512,"price":26.4592,"value":13547.1104,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the \"Heyman Daigle Trust\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.7133 to $26.7111. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Heyman Daigle Trust."}],"balance_after":24595,"source":{"system":"sec-edgar","filing":"0001584759-26-000007","document":"form4-01222026_100111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000007/form4-01222026_100111.xml","form_type":"4"}},{"id":935021,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T00:19:28.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":12.0046,"value":38414.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":213072,"source":{"system":"sec-edgar","filing":"0001584759-26-000006","document":"form4-01212026_120124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000006/form4-01212026_120124.xml","form_type":"4"}},{"id":935020,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T00:19:28.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":3500,"price":12.0046,"value":42016.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":41800,"source":{"system":"sec-edgar","filing":"0001584759-26-000006","document":"form4-01212026_120124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000006/form4-01212026_120124.xml","form_type":"4"}},{"id":941007,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:11:16.000Z","date":"2026-01-09","kind":"sale","planned":true,"acquired":false,"shares":4285,"price":25.0001,"value":107125.4285,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the \"Heyman Daigle Trust\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $25.00 to $25.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by the Heyman Daigle Trust."}],"balance_after":25107,"source":{"system":"sec-edgar","filing":"0001584759-26-000004","document":"form4-01122026_100112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000004/form4-01122026_100112.xml","form_type":"4"}},{"id":941006,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:11:16.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":8015,"price":25.035,"value":200655.525,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the \"Heyman Daigle Trust\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $25.00 to $25.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by the Heyman Daigle Trust."}],"balance_after":29392,"source":{"system":"sec-edgar","filing":"0001584759-26-000004","document":"form4-01122026_100112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000004/form4-01122026_100112.xml","form_type":"4"}},{"id":941005,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:11:16.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":1620,"price":25,"value":40500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by RAHD Capital LLC, for which the Reporting Person serves as a managing member."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by RAHD Capital LLC."}],"balance_after":25545,"source":{"system":"sec-edgar","filing":"0001584759-26-000004","document":"form4-01122026_100112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000158475926000004/form4-01122026_100112.xml","form_type":"4"}},{"id":945710,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:46:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026."}],"balance_after":40000,"derivative":{"exercise_price":8.17,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001584759-26-000003","document":"form4-01062026_090104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475926000003/form4-01062026_090104.xml","form_type":"4"}},{"id":1024075,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-03T23:18:01.000Z","date":"2025-10-03","kind":"exercise","planned":false,"acquired":false,"shares":1447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":52253,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":1447},"source":{"system":"sec-edgar","filing":"0001584759-25-000004","document":"form4-10032025_111055.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475925000004/form4-10032025_111055.xml","form_type":"4"}},{"id":1024074,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-03T23:18:01.000Z","date":"2025-10-03","kind":"exercise","planned":false,"acquired":false,"shares":18125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.6,"expiration_date":"2028-06-28","underlying":"Common Stock","underlying_shares":18125},"source":{"system":"sec-edgar","filing":"0001584759-25-000004","document":"form4-10032025_111055.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475925000004/form4-10032025_111055.xml","form_type":"4"}},{"id":1024073,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-03T23:18:01.000Z","date":"2025-10-03","kind":"exercise","planned":false,"acquired":false,"shares":13228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":33700,"derivative":{"exercise_price":1.6,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":13228},"source":{"system":"sec-edgar","filing":"0001584759-25-000004","document":"form4-10032025_111055.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475925000004/form4-10032025_111055.xml","form_type":"4"}},{"id":1024072,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-03T23:18:01.000Z","date":"2025-10-03","kind":"exercise","planned":false,"acquired":true,"shares":1447,"price":3.75,"value":5426.25,"ownership":{"direct":true},"balance_after":45300,"source":{"system":"sec-edgar","filing":"0001584759-25-000004","document":"form4-10032025_111055.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475925000004/form4-10032025_111055.xml","form_type":"4"}},{"id":1024071,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-03T23:18:01.000Z","date":"2025-10-03","kind":"exercise","planned":false,"acquired":true,"shares":31353,"price":1.6,"value":50164.8,"ownership":{"direct":true},"balance_after":43853,"source":{"system":"sec-edgar","filing":"0001584759-25-000004","document":"form4-10032025_111055.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000158475925000004/form4-10032025_111055.xml","form_type":"4"}},{"id":1117424,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:26:03.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":33500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":33500,"derivative":{"exercise_price":0.95,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0001415889-25-016266","document":"form4-06092025_080655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000141588925016266/form4-06092025_080655.xml","form_type":"4"}},{"id":1276598,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:38:18.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":23014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":23014,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":23014},"source":{"system":"sec-edgar","filing":"0001415889-25-003520","document":"form4-02102025_100215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588925003520/form4-02102025_100215.xml","form_type":"4"}},{"id":1309734,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:44:52.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025."}],"balance_after":35000,"derivative":{"exercise_price":8.26,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-000785","document":"form4-01062025_090141.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000141588925000785/form4-01062025_090141.xml","form_type":"4"}},{"id":1382946,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T20:18:56.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":753,"price":30.0021,"value":22591.5813,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member."}],"balance_after":27165,"source":{"system":"sec-edgar","filing":"0001415889-24-025500","document":"form4-10222024_081053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924025500/form4-10222024_081053.xml","form_type":"4"}},{"id":1382945,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T20:18:56.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":817,"price":30.003,"value":24512.451,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":123673,"source":{"system":"sec-edgar","filing":"0001415889-24-025500","document":"form4-10222024_081053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924025500/form4-10222024_081053.xml","form_type":"4"}},{"id":1384811,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:06:43.000Z","date":"2024-10-15","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":27.6719,"value":35143.313,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.1521 to $27.9631. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":124490,"source":{"system":"sec-edgar","filing":"0001415889-24-025381","document":"form4-10172024_091039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924025381/form4-10172024_091039.xml","form_type":"4"}},{"id":1389328,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-08T22:54:49.000Z","date":"2024-10-04","kind":"sale","planned":true,"acquired":false,"shares":2825,"price":27.5057,"value":77703.6025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":125760,"source":{"system":"sec-edgar","filing":"0001415889-24-024899","document":"form4-10082024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924024899/form4-10082024_101045.xml","form_type":"4"}},{"id":1392045,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T22:43:46.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":518,"price":27.5373,"value":14264.3214,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.52 to $27.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":128585,"source":{"system":"sec-edgar","filing":"0001415889-24-024668","document":"form4-10032024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924024668/form4-10032024_101042.xml","form_type":"4"}},{"id":1403629,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T20:17:36.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":22.408,"value":28458.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.11 to $22.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":129103,"source":{"system":"sec-edgar","filing":"0001415889-24-023610","document":"form4-09182024_080929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924023610/form4-09182024_080929.xml","form_type":"4"}},{"id":1429381,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-19T23:49:46.000Z","date":"2024-08-15","kind":"sale","planned":true,"acquired":false,"shares":620,"price":23.7027,"value":14695.674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $23.44 to $23.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":130373,"source":{"system":"sec-edgar","filing":"0001415889-24-021644","document":"form4-08192024_110843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924021644/form4-08192024_110843.xml","form_type":"4"}},{"id":1429380,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-19T23:49:46.000Z","date":"2024-08-15","kind":"sale","planned":true,"acquired":false,"shares":650,"price":22.8162,"value":14830.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.36 to $23.3588. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":130993,"source":{"system":"sec-edgar","filing":"0001415889-24-021644","document":"form4-08192024_110843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924021644/form4-08192024_110843.xml","form_type":"4"}},{"id":1442889,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-02T23:22:23.000Z","date":"2024-07-31","kind":"sale","planned":true,"acquired":false,"shares":649,"price":27.5,"value":17847.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member."}],"balance_after":27918,"source":{"system":"sec-edgar","filing":"0001415889-24-020685","document":"form4-08022024_110819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924020685/form4-08022024_110819.xml","form_type":"4"}},{"id":1442888,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-02T23:22:23.000Z","date":"2024-07-31","kind":"sale","planned":true,"acquired":false,"shares":1702,"price":27.5059,"value":46815.0418,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":131643,"source":{"system":"sec-edgar","filing":"0001415889-24-020685","document":"form4-08022024_110819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924020685/form4-08022024_110819.xml","form_type":"4"}},{"id":1452597,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-17T23:25:26.000Z","date":"2024-07-15","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":24.8006,"value":31496.762,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $24.22 to $25.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":133345,"source":{"system":"sec-edgar","filing":"0001415889-24-019731","document":"form4-07172024_110722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924019731/form4-07172024_110722.xml","form_type":"4"}},{"id":1473189,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T23:20:38.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":21.4787,"value":27277.949,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $21.22 to $22.0783. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":134615,"source":{"system":"sec-edgar","filing":"0001415889-24-017715","document":"form4-06202024_110634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924017715/form4-06202024_110634.xml","form_type":"4"}},{"id":1478517,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:21:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":25600,"derivative":{"exercise_price":7.9,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":25600},"source":{"system":"sec-edgar","filing":"0001415889-24-016903","document":"form4-06142024_080630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000141588924016903/form4-06142024_080630.xml","form_type":"4"}},{"id":1484478,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:22:51.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024."}],"balance_after":67500,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001415889-24-016214","document":"form4-06102024_080647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000141588924016214/form4-06102024_080647.xml","form_type":"4"}},{"id":1508992,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T23:46:33.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":23.7399,"value":30149.673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $23.525 to $24.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":135885,"source":{"system":"sec-edgar","filing":"0001415889-24-013833","document":"form4-05202024_110525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924013833/form4-05202024_110525.xml","form_type":"4"}},{"id":1541902,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-15T23:03:32.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":649,"price":25,"value":16225.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member."}],"balance_after":28567,"source":{"system":"sec-edgar","filing":"0001415889-24-010825","document":"form4-04152024_110425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010825/form4-04152024_110425.xml","form_type":"4"}},{"id":1541901,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-15T23:03:32.000Z","date":"2024-04-15","kind":"sale","planned":true,"acquired":false,"shares":80,"price":20.6773,"value":1654.184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $20.64 to $20.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":137155,"source":{"system":"sec-edgar","filing":"0001415889-24-010825","document":"form4-04152024_110425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010825/form4-04152024_110425.xml","form_type":"4"}},{"id":1541900,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-15T23:03:32.000Z","date":"2024-04-15","kind":"sale","planned":true,"acquired":false,"shares":1190,"price":19.9403,"value":23728.957,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $19.61 to $20.5558. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":137235,"source":{"system":"sec-edgar","filing":"0001415889-24-010825","document":"form4-04152024_110425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010825/form4-04152024_110425.xml","form_type":"4"}},{"id":1541899,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-15T23:03:32.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":5045,"price":25.0306,"value":126279.377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.00 to $25.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":138.425,"source":{"system":"sec-edgar","filing":"0001415889-24-010825","document":"form4-04152024_110425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010825/form4-04152024_110425.xml","form_type":"4"}},{"id":1564823,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-21T22:41:07.000Z","date":"2024-03-19","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":14.5029,"value":18418.683,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.50 to $14.725. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":143470,"source":{"system":"sec-edgar","filing":"0001415889-24-008883","document":"form4-03212024_100359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924008883/form4-03212024_100359.xml","form_type":"4"}},{"id":1614584,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T21:59:10.000Z","date":"2024-02-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":367446,"price":62.5,"value":22965375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the \"Cash Amount\").  At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-005525","document":"form4-02272024_090252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000141588924005525/form4-02272024_090252.xml","form_type":"4"}},{"id":1633769,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T00:41:45.000Z","date":"2024-02-15","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":17.4153,"value":22117.431,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $17.25 to $17.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":144740,"source":{"system":"sec-edgar","filing":"0001415889-24-004495","document":"form4-02212024_120234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004495/form4-02212024_120234.xml","form_type":"4"}},{"id":1633767,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-21T00:32:13.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":29205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."}],"balance_after":29205,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":29205},"source":{"system":"sec-edgar","filing":"0001415889-24-004490","document":"form4a-02212024_120255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004490/form4a-02212024_120255.xml","form_type":"4/A","original_submission_date":"2024-02-15"}},{"id":1640966,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T01:52:32.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":21043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":21043,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":21043},"source":{"system":"sec-edgar","filing":"0001415889-24-004018","document":"form4-02162024_010226.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004018/form4-02162024_010226.xml","form_type":"4"}},{"id":1663922,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T01:10:19.000Z","date":"2024-01-30","kind":"sale","planned":true,"acquired":false,"shares":1270,"price":16.4091,"value":20839.557,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.10 to $16.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":146010,"source":{"system":"sec-edgar","filing":"0001415889-24-002220","document":"form4-02022024_010213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924002220/form4-02022024_010213.xml","form_type":"4"}},{"id":1700064,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:29:13.000Z","date":"2023-12-22","kind":"sale","planned":true,"acquired":false,"shares":35,"price":13,"value":455.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member."}],"balance_after":29216,"source":{"system":"sec-edgar","filing":"0001209191-23-059715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059715/doc4.xml","form_type":"4"}},{"id":1700063,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:29:13.000Z","date":"2023-12-22","kind":"sale","planned":true,"acquired":false,"shares":168,"price":13,"value":2184.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."}],"balance_after":147280,"source":{"system":"sec-edgar","filing":"0001209191-23-059715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059715/doc4.xml","form_type":"4"}},{"id":1700062,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:29:13.000Z","date":"2023-12-21","kind":"sale","planned":true,"acquired":false,"shares":6,"price":13,"value":78.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member."}],"balance_after":29251,"source":{"system":"sec-edgar","filing":"0001209191-23-059715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059715/doc4.xml","form_type":"4"}},{"id":1700061,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:29:13.000Z","date":"2023-12-21","kind":"sale","planned":true,"acquired":false,"shares":7,"price":13,"value":91.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023."}],"balance_after":147448,"source":{"system":"sec-edgar","filing":"0001209191-23-059715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059715/doc4.xml","form_type":"4"}},{"id":1702195,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-21T21:28:49.000Z","date":"2023-12-20","kind":"sale","planned":true,"acquired":false,"shares":1915,"price":13.0232,"value":24939.428,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member."}],"balance_after":29257,"source":{"system":"sec-edgar","filing":"0001209191-23-059431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059431/doc4.xml","form_type":"4"}},{"id":1702194,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-21T21:28:49.000Z","date":"2023-12-20","kind":"sale","planned":true,"acquired":false,"shares":2110,"price":13.0202,"value":27472.622,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":147455,"source":{"system":"sec-edgar","filing":"0001209191-23-059431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059431/doc4.xml","form_type":"4"}},{"id":1702193,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-21T21:28:49.000Z","date":"2023-12-19","kind":"sale","planned":true,"acquired":false,"shares":255,"price":13,"value":3315.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023."}],"balance_after":149565,"source":{"system":"sec-edgar","filing":"0001209191-23-059431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123059431/doc4.xml","form_type":"4"}},{"id":1853866,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T20:54:15.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":20500,"derivative":{"exercise_price":6.33,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919123037394/doc4.xml","form_type":"4"}},{"id":1858349,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T21:39:29.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":21500,"derivative":{"exercise_price":5.59,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-23-036427","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919123036427/doc4.xml","form_type":"4"}},{"id":1923779,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:19:25.000Z","date":"2023-02-23","kind":"grant","planned":false,"acquired":true,"shares":34458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":34458,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":34458},"source":{"system":"sec-edgar","filing":"0001209191-23-023666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123023666/doc4.xml","form_type":"4"}},{"id":1990395,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-28T02:54:29.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":20657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is subject to an early exercise provision and the shares underlying the option vest in 48 equal monthly installments beginning on January 14, 2021."}],"balance_after":20657,"derivative":{"exercise_price":2.48,"expiration_date":"2032-08-12","underlying":"Common Stock","underlying_shares":20657},"source":{"system":"sec-edgar","filing":"0001209191-23-013522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013522/doc4.xml","form_type":"4"}},{"id":1990394,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:54:29.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":31172,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of  Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares held of record by RAHD Capital LLC for which the reporting person serves as a managing member."}],"balance_after":31172,"source":{"system":"sec-edgar","filing":"0001209191-23-013522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013522/doc4.xml","form_type":"4"}},{"id":1990393,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:54:29.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":37407,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of  Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the reporting person serves as trustee."}],"balance_after":37407,"source":{"system":"sec-edgar","filing":"0001209191-23-013522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013522/doc4.xml","form_type":"4"}},{"id":1990392,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:54:29.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":149820,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of  Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""}],"balance_after":149820,"source":{"system":"sec-edgar","filing":"0001209191-23-013522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013522/doc4.xml","form_type":"4"}},{"id":2165060,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-09-06T23:23:26.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":16500,"derivative":{"exercise_price":0.42,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-22-048881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919122048881/doc4.xml","form_type":"4"}},{"id":2223772,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T21:32:03.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date."}],"balance_after":19000,"derivative":{"exercise_price":2.22,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001567619-22-013257","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000156761922013257/doc1.xml","form_type":"4"}},{"id":2226698,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-18T00:22:14.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":53700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B)  one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":53700,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":53700},"source":{"system":"sec-edgar","filing":"0001209191-22-038200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919122038200/doc4.xml","form_type":"4"}},{"id":2241258,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T21:41:49.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 2, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":19500,"derivative":{"exercise_price":13.56,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001209191-22-034620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919122034620/doc4.xml","form_type":"4"}},{"id":2502251,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T21:57:13.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date."}],"balance_after":19000,"derivative":{"exercise_price":9.86,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001567619-21-020858","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000156761921020858/doc1.xml","form_type":"4"}},{"id":2567311,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T22:19:21.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":682,"price":25.0347,"value":17073.6654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 682 shares sold in the price range of $25.00 to $25.19 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":216272,"source":{"system":"sec-edgar","filing":"0001209191-21-056461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121056461/doc4.xml","form_type":"4"}},{"id":2567310,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T22:19:21.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":706,"price":25.0511,"value":17686.0766,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 706 shares sold in the price range of $25.00 to $25.28 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":216954,"source":{"system":"sec-edgar","filing":"0001209191-21-056461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121056461/doc4.xml","form_type":"4"}},{"id":2570391,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T20:03:31.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":601,"price":25.0133,"value":15032.9933,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 601 shares sold in the price range of $25.00 to $25.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":217660,"source":{"system":"sec-edgar","filing":"0001209191-21-055871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121055871/doc4.xml","form_type":"4"}},{"id":2570390,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T20:03:31.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":479,"price":25.1005,"value":12023.1395,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 479 shares sold in the price range of $25.05 to $25.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":218261,"source":{"system":"sec-edgar","filing":"0001209191-21-055871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121055871/doc4.xml","form_type":"4"}},{"id":2574397,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-09T20:36:41.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":1086,"price":25.1125,"value":27272.175,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 1,086 shares sold in the price range of $25.00 to $25.26 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":218740,"source":{"system":"sec-edgar","filing":"0001209191-21-055295","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121055295/doc4.xml","form_type":"4"}},{"id":2625665,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-23T20:07:22.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on June 12, 2021."}],"balance_after":5781,"derivative":{"exercise_price":28.33,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001209191-21-047970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121047970/doc4.xml","form_type":"4"}},{"id":2662933,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T23:46:44.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":16625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":16625,"derivative":{"exercise_price":19.03,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":16625},"source":{"system":"sec-edgar","filing":"0001209191-21-041743","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121041743/doc4.xml","form_type":"4"}},{"id":2675055,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T21:30:47.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":16333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 2, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":16333,"derivative":{"exercise_price":32.29,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":16333},"source":{"system":"sec-edgar","filing":"0001209191-21-039237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121039237/doc4.xml","form_type":"4"}},{"id":2680843,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:05:27.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":14800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021."}],"balance_after":14800,"derivative":{"exercise_price":15.26,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":14800},"source":{"system":"sec-edgar","filing":"0000899243-21-022013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000089924321022013/doc4.xml","form_type":"4"}},{"id":2685828,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":975,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"All of the shares subject to the option are vested and immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants."}],"balance_after":7951,"derivative":{"exercise_price":2.95,"expiration_date":"2027-08-16","underlying":"Common Stock","underlying_shares":975},"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685827,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":975,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"All of the shares subject to the option are vested and immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants."}],"balance_after":7951,"derivative":{"exercise_price":2.95,"expiration_date":"2027-08-16","underlying":"Common Stock","underlying_shares":975},"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685826,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":1950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"All of the shares subject to the option are vested and immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family."}],"balance_after":15901,"derivative":{"exercise_price":2.95,"expiration_date":"2027-08-16","underlying":"Common Stock","underlying_shares":1950},"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685825,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":2,"price":34.67,"value":69.34,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685824,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":209,"price":33.7882,"value":7061.7338,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $33.875, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants."}],"balance_after":2,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685823,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":764,"price":32.1507,"value":24563.1348,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.815, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants."}],"balance_after":211,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685822,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":975,"price":975,"value":950625.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants."}],"balance_after":975,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685821,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":2,"price":34.67,"value":69.34,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685820,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":230,"price":33.7465,"value":7761.695,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $33.875, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants."}],"balance_after":2,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685819,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":743,"price":32.1618,"value":23896.2174,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.46, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants."}],"balance_after":232,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685818,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":975,"price":2.95,"value":2876.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants."}],"balance_after":975,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685817,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":5,"price":34.67,"value":173.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685816,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":553,"price":33.6105,"value":18586.6065,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.055 to $33.875, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family."}],"balance_after":5,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685815,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":1392,"price":32.1509,"value":44754.0528,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.01 to $32.815, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (6), (7), (9) and (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family."}],"balance_after":558,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2685814,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:11:43.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":1950,"price":2.95,"value":5752.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family."}],"balance_after":1950,"source":{"system":"sec-edgar","filing":"0001209191-21-037144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121037144/doc4.xml","form_type":"4"}},{"id":2696568,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-25T23:01:07.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2022 annual meeting of stockholders."}],"balance_after":16500,"derivative":{"exercise_price":4.07,"expiration_date":"2031-05-23","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-21-035784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121035784/doc4.xml","form_type":"4"}},{"id":2698226,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T23:30:36.000Z","date":"2021-05-24","kind":"sale","acquired":false,"shares":100,"price":25,"value":2500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":219826,"source":{"system":"sec-edgar","filing":"0001209191-21-035525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121035525/doc4.xml","form_type":"4"}},{"id":2698225,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T23:30:36.000Z","date":"2021-05-21","kind":"sale","acquired":false,"shares":600,"price":25.25,"value":15150.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 600 shares sold in the price range of $25.18 to $25.35 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":219926,"source":{"system":"sec-edgar","filing":"0001209191-21-035525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121035525/doc4.xml","form_type":"4"}},{"id":2698224,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T23:30:36.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":700,"price":25.0829,"value":17558.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 700 shares sold in the price range of $25.00 to $25.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":220526,"source":{"system":"sec-edgar","filing":"0001209191-21-035525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121035525/doc4.xml","form_type":"4"}},{"id":2707221,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":28195,"kind":"person","name":"Heyman Richard A.","position":1,"cik":"0001584759","reported_name":"Heyman Richard A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-19T00:22:17.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":2161,"price":25.3195,"value":54715.4395,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average share price of an aggregate total of 2,161 shares sold in the price range of $25.00 to $25.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."}],"balance_after":221226,"source":{"system":"sec-edgar","filing":"0001209191-21-033817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1584759/000120919121033817/doc4.xml","form_type":"4"}}],"next_cursor":"2021-05-19T00:22:17.000000Z,2707221"}